However, zeste homolog 2 (EZH-2), a histone methyltrasefrase found in 62.5% of SCLCs [82], increases the expression of major histocompatibility complex class I (MHC-I) in SCLC and may represent a promising approach to improving ICI therapy [83,84]. Here, EZH2 is linked to small cell lung carcinoma.